Nationwide Fund Advisors’s Blueprint Medicines BPMC Stock Holding History

Nationwide Fund Advisors’s Portfolio BPMC Stock Details BPMC Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q4	–	Sell	-55,392	Closed	-$3.86M	–	295
2017 Q3	$3.86M	Buy	55,392 +3,858	+7%	+$206K	0.02%	1132
2017 Q2	$2.61M	Buy	51,534 +29,742	+136%	+$1.26M	0.01%	1315
2017 Q1	$871K	Buy	21,792 +9,410	+76%	+$337K	﹤0.01%	1844
2016 Q4	$347K	Sell	12,382 -587	-5%	-$17.7K	﹤0.01%	2360
2016 Q3	$385K	Hold	12,969	–	–	﹤0.01%	2303
2016 Q2	$263K	Buy	12,969 +6,909	+114%	+$126K	﹤0.01%	2479
2016 Q1	$109K	Hold	6,060	–	–	﹤0.01%	2781
2015 Q4	$160K	Hold	6,060	–	–	﹤0.01%	2650
2015 Q3	$129K	Hold	6,060	–	–	﹤0.01%	2797
2015 Q2	$161K	Buy	+6,060	New	+$173K	﹤0.01%	2818

Other funds holding BPMC

Fidelity Investments Boston, Massachusetts $1.9T AUM 41.92% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

TGI

TRV GP II Boston, Massachusetts $1.34M AUM 67.55% 1-Year Est. Return

Lord, Abbett & Co Jersey City, New Jersey $30.6B AUM 57.44% 1-Year Est. Return

OppenheimerFunds New York $80.4B AUM 15.1% 1-Year Est. Return

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

HIM

Hillhouse Investment Management Grand Cayman, Cayman Islands $3.13B AUM 7.29% 1-Year Est. Return

Nationwide Fund Advisors's BPMC Position: Q4 2017 in Review

Nationwide Fund Advisors sold out of Blueprint Medicines (BPMC) in Q4 2017, closing a stake of 55,392 shares — an estimated $3.86M sold.

Nationwide Fund Advisors first reported a position in BPMC in Q2 2015 and held it in 10 quarters. The position peaked at $3.86M in Q3 2017. 170 funds tracked by Wall St. Rank hold BPMC as of Q4 2017.

Nationwide Fund Advisors reported no remaining Blueprint Medicines position as of Q4 2017 after selling out during the quarter.
Nationwide Fund Advisors sold 55,392 Blueprint Medicines shares in Q4 2017, an estimated $3.86M.
Nationwide Fund Advisors first reported a position in Blueprint Medicines in Q2 2015 and held it in 10 quarters.
Nationwide Fund Advisors's Blueprint Medicines position peaked at $3.86M in Q3 2017.
170 funds tracked by Wall St. Rank held Blueprint Medicines as of Q4 2017.

Based on Nationwide Fund Advisors's 13F filing for Q4 2017, filed 1 Feb 2018.